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Background. Studies of Tuberculosis (TB) case contacts are increasingly being utilised for understanding the relationship
between M. tuberculosis and the human host and for assessing new interventions and diagnostic tests. We aimed to identify
the incidence rate of new TB cases among TB contacts and to relate this to their initial Mantoux and ELISPOT test results.
Methods and Findings. After initial Mantoux and ELISPOT tests and exclusion of co-prevalent TB cases, we followed 2348
household contacts of sputum smear positive TB cases. We visited them at 3 months, 6 months, 12 months, 18 months and
24 months, and investigated those with symptoms consistent with TB. Those who were diagnosed separately at a government
clinic had a chest x-ray. Twenty six contacts were diagnosed with definite TB over 4312 person years of follow-up (Incidence
rate 603/100,000 person years; 95% Confidence Interval, 370–830). Nine index and secondary case pairs had cultured isolates
available for genotyping. Of these, 6 pairs were concordant and 3 were discordant. 2.5% of non-progressors were HIV positive
compared to 12% of progressors (HR 6.2; 95% CI 1.7–22.5; p=0.010). 25 secondary cases had initial Mantoux results, 14 (56%)
were positive ; 21 had initial ELISPOT results, 11 (52%) were positive; 15 (71%) of 21 tested were positive by one or the other
test. Of the 6 contacts who had concordant isolates with their respective index case, 4 (67%) were Mantoux positive at
recruitment, 3 (50%) were ELISPOT positive; 5 (83%) were positive by one or other of the two tests. ELISPOT positive contacts,
and those with discordant results, had a similar rate of progression to those who were Mantoux positive. Those negative on
either or both tests had the lowest rate of progression. Conclusions. The incidence rate of TB disease in Gambian TB case
contacts, after screening for co-prevalent cases, was 603/100,000 person years. Since initial ELISPOT test and Mantoux tests
were each positive in only just over half of cases, but 71% were positive by one or other test, positivity by either might be the
best indication for preventive treatment. These data do not support the replacement of the Mantoux test by an ELISPOT test in
The Gambia or similar settings.
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INTRODUCTION
Household contacts of tuberculosis (TB) cases have a relatively high
prevalence of TB disease when screened [1] and a higher incidence
rate of TB disease than the general population in the first years after
exposure, the rate varying across different locations and popula-
tions[2–5]. It is likely that contacts of known TB cases contribute
greatly to the overall TB disease burden in certain settings. For
example, in West Africa, up to 45% of newly diagnosed TB cases
have a known TB contact [6,7]. TB case contact studies are being
engaged increasingly as platforms for studying TB and have
potential in relation to the assessment of new diagnostic tests and
interventions,includingvaccines. However,moreneedstobe known
about the epidemiology of TB in case contacts to assist in the
planning and implementation of such studies.
Cross-sectional studies have suggested promise for interferon-
gamma T cell based tests in the diagnosis M. tuberculosis infection
and TB disease[8–12]. However, longitudinal studies suggest
caution [13,14], especially in interpreting a result when there is no
known recent TB contact[15]. Furthermore, it is not known what
proportion of those who are TB case contacts, and become cases
themselves, have a positive test from an initial screen. Recently,
the British National Institute for Health and Clinical Excellence
(NICE) published recommendations suggesting that the traditional
Mantoux skin test and an interferon-gamma test be used in a two-
step manner – the Mantoux test as a screening tool and an
interferon-gamma test as confirmation [16]. The evidence to
support such an approach is lacking.
In this study we followed a large number of TB case contacts for
the development of TB disease and related their initial Mantoux and
ELISPOT test results to the likelihood of progression to TB disease.
MATERIALS AND METHODS
Study population
Between June 2002 and October 2004, TB cases and their
household contacts were enrolled in a prospective cohort study in
the Greater Banjul region of The Gambia, West Africa. We
recruited, from the major government TB clinic and the Medical
Research Council (MRC) outpatients’ clinic, sputum smear positive
pulmonary TB cases aged at least 15 years old, who had at least one
householdcontact living with them.An indexcasewasdefinedas the
first TB case identified in a household. Household contacts were
defined as individuals at least 6 months of age living the majority of
the time on the same compound as the respective index TB case,
sharing meals and identifying a common household head. Written
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At the time of recruitment, contacts were interviewed and
immediately afterwards had a blood sample taken for ELISPOT
and HIV test, followed by a Mantoux test (2 Tuberculin Units
[TU], PPD RT23 Statens Serum Institut, http:/www.ssi.dk). A
maximum of 12 contacts had an ELISPOT test per day, others
were randomly excluded. Those with symptoms, or a positive
Mantoux test, were investigated for TB. The current policy in The
Gambia is not to give Mantoux positive individuals preventive
therapy. A co-prevalent TB case was defined as a household
contact diagnosed with TB who had symptoms that commenced
within 2 months of the recruitment of the respective index case.
The results of the initial screening, yielding 33 co-prevalent cases,
have been published elsewhere[1]. We performed five follow-up
visits (at 3, 6, 12, 18 and 24 months after recruitment) to each
household and referred those with symptoms to the MRC TB
clinic. All study participants had free access to the MRC TB clinic
for treatment for any illness during this period. Any patients with
symptoms of pulmonary disease received a chest X-ray and
sputum analysis for AFB smear analysis and culture. If TB disease
was bacteriologically confirmed, or clinically suspected in smear-
negative or extra-pulmonary cases, patients were referred for a
free standard six month TB treatment course to the Gambian
National TB Treatment program. For those contacts who died, we
designed a modified verbal autopsy form, focused on TB
symptoms. This was administered by a trained field worker to
family members and interpreted by clinicians.
Secondary Case definition
All contacts with symptoms, consistent with TB, that commenced at
least 2 months after their respective index case was diagnossed, or
with a positive Mantoux test (at least 10 mm of induration) at any
follow-up time point, were considered to be possible secondary TB
cases. They were asked to have a chest X-ray and provide sputum if
they had a productive cough. All those initially Mantoux negative at
recruitment were asked to have a repeat Mantoux test at 3 months.
Those that were Mantoux positive were offered a chest X-ray. A
diagnosis of a secondary TB case was based on the chest X-ray and
sputum smear and culture results, and/or their response to a course
of TB treatment if a trial of therapy had been considered appropriate.
Theywereclassifiedashavingpulmonaryorextra-pulmonarydisease
by consensus of two infectious diseases physicians and one paedia-
trician specialised in the diagnosis and management of TB cases.
An alternative strategy was devised with respect to those contacts
who sought a diagnosis only at a government clinic, where sputum
culture was not available. Names and ages of all TB cases treated at
the government health clinics during the course of the study were
recorded. Those that matched with contacts participating in our
study, using anage category matching within5 years, were re-visited
to confirm whether they had had TB treatment or not. Those that
confirmed having taken treatment,wereaskedtohavea chestX-ray.
Each radiograph was reviewed by the two infectious diseases
physicians, and/or pediatrician when the participant was a child.
After review, a consensus opinion regarding the diagnosis of a
secondary TB case was formed . Those with no evidence of TB on
chest X-ray were defined as ‘not definite’.
Laboratory procedures
Sputum samples were prepared for smear using auramine-phenol,
and cultured using Lowenstein-Jensen medium and the BACTEC
9000 MB system (Becton Dickinson) for identification of M.
tuberculosis, as previously described[17]. For molecular subtyping of
index case isolates, we extracted mycobacterial DNA using CTAB
and chloroform[18]. We performed spoligotyping using mem-
branes from Isogen Biosciences (http:/www.isogen-lifescience.
com), as previously described[19]. When the isolate of an index
case and the isolate of a diseased contact from the same household
shared the same spoligotype pattern (genotype), these were
referred to as concordant genotypes. Isolates that shared the same
spoligotype pattern except for one of 43 spacers, were also
classified as concordant genotypes. All others were classified as
discordant genotypes.
The ex-vivo ELISPOT assays for IFN-c were performed on fresh
samplesonsiteaspreviouslydescribed.[11]Pooledsequential15-mer
peptides, overlapping by 10 amino-acid residues, of ESAT-6 and
CFP-10proteins(ABC,ImperialCollege,London,UK)wereusedas
stimulatory antigens at 5 mg/ml. The positive control was
phytohaemaglutinin (PHA; Sigma-Aldrich, UK). All antigens were
tested in duplicate wells. Assays were scored by an ELISPOT
counter (AID-GmbH, Strassberg, Germany). Positive test wells were
pre-defined as containing at least eight spot forming units (SFU)
more than negative control wells.[20] For a positive ESAT-6/CFP-
10 result it was necessary for at least one of the pools of overlapping
peptides to be positive.PHA wellswere set to at least 150 SFU/well/
2610
5 above negative control wells. Negative control wells were
required to have less than 20 SFU. These criteria are the same as we
have previously documented and are more stringent than those
recommended for the commercial T-spot assay[21].
Testing for HIV-1 and HIV-2 infection was by competitive
ELISA (Wellcome Laboratories, Dartford, Kent, Uk) and Western
blot (Diagnostics Pasteur, http:/www.sanofipasteur.com) as previ-
ously described[22]. Those individuals who tested positive were
referred to the onsite MRC HIV clinic for clinical care and follow-
up, being eligible for consideration for free anti-retroviral therapy
according to set criteria.
Data management and statistical analysis
The number of SFU in each ELISPOT well were automatically
entered into a database. All other data were entered using double
data entry into an ACCESS database and checked for errors[23].
We used Cox proportional hazards regression to assess the
relationship between risk factors and rate of progression to disease
in TB contacts, having confirmed non-violation of the propor-
tional hazards assumption. Results were reported as unadjusted
and adjusted hazard ratios (HR) and their 95% confidence
intervals (CI). All statistical analyses were conducted using Stata
software (version 8; Stata Corp, http://www.statacom).
RESULTS
Of the 2381 contacts of 317 sputum smear and culture positive TB
cases,33 were excluded fromfollow-up,havingbeenidentified asco-
prevalent cases. Figure 1 shows the numbers of contacts assessed at
each of the five follow-up points over 2 years: 24 died and 191 were
lost to the study through migration out of the study area; 82–93% of
those resident at each time point were assessed for symptoms of TB.
Twentysix contactswerediagnosed with as secondary TB cases over
4312 person years of follow-up. A further 6 contacts were treated for
TBbutthediagnosiswasconsidered notdefinite.Ofthe 24 whodied
duriing follow-up: four were HIV positive, two of whom had been a
TBsuspectbuthad normalchestX-rays;11 clearlydiedofa non-TB
cause; five had some history on verbal autopsy suspicious for TB,
four of these had been investigated during follow-up and had normal
investigations; and a verbal autopsy was not possible for four.
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contact first became a TB suspect: 14 were diagnosed in the first
6 months after the co-prevalent window period, the other 12 were
distributed over the next 17 months. Table 1 shows the
characteristics of those who progressed to disease versus those
who did not. Progressors had a similar gender and ethnicity split
than those who did not progress. Interestingly there was not a
strong relationship with sleeping proximity to a TB case. As
expected, while only 2.5% of non-progressors were HIV positive,
12% (3 of 24) progressors were HIV positive at recruitment. This
difference was significant in the univariable (HR 6.0; 95% CI 1.8–
20.0; p=0.020) and multivariable analysis (HR 6.2; 95% CI 1.7–
22.5; p=0.010), and accounted for some of the age difference
between progressors and non-progressors. No information was
available regarding the level of immunosuppression of the HIV
positive progressors. BCG scar was not significantly associated
with protection against progression to disease.
Table 2 provides details of each individual TB secondary case in
relation to their recruitment Mantoux and ELISPOT results. At
recruitment, 14 (56%) of 25 that were tested, and later diagnosed
as cases, were Mantoux positive; 11 (52%) of 21 tested were
ELISPOT positive; and 15 (71%) of 21 tested were positive by one
or the other of the two tests. The agreement, in the secondary
cases, between the two tests at recruitment was 61.9% (kap-
pa=0.24). Nine index case and secondary case pairs had cultured
isolates available for molecular genotyping. Of these, 6 pairs were
concordant and 3 were discordant. Of the 6 contacts who had
concordant isolates with their respective index case, 4 (67%) were
Mantoux positive at recruitment, 3 (50%) were ELISPOT positive
and 5 (83%) were positive by one or other of the two tests.
Table 3 shows the incidence rate of progression to disease
according to recruitment Mantoux and ELISPOT results. Those
contacts who were ELISPOT positive and those who were
ELISPOT negative at recruitment had a similar rate of progression
to disease as those who were Mantoux postive and negative
respectively. Those negative on either or both tests had the lowest
incidence rate of progression. Of note, those with discordant results
had a similar rate of progression to those who were positive on either
test. Taking into consideration the 21 cases with ELISPOT and
Mantoux results at recruitment in relation to current international
guidelines for preventive therapy: 15 would have been captured by
accepting a positive result on one or both tests, 11 would have been
captured by either the Mantoux or ELISPOT test, but only 7 would
have been captured by a requirement to be positive on both tests–
over half (8 of 15) that were intially positve by either test had
discordant results at recruitment. Using Cox regression modelling,
the crude and adjusted Hazard ratios for a positive test in relation to
becoming a secondary case were: 1.9 (95% CI: 1.0–4.7) and 1.8
(95% CI 0.8–4.1) respectively for the Mantoux test and 1.9 (0.8–4.5)
and 1.8 (0.8–4.2) for the ELISPOT test.
DISCUSSION
After an initial screen for co-prevalent disease[1], we activelyfollowed
over 2000 householdcontactsof sputumsmear positive TB cases for a
total of 4312 person years. Twenty-six secondary cases were
identified, giving an incidence rate of 603/100,000 person years.
HIV positivity, despite a low prevalence in this population, was the
one significant risk factor for progression to TB disease. Wewere able
to calculate the incidence rates of secondary disease in relation to
initial Mantoux and ELISPOT results and to show how many
secondary cases were ‘captured’ by a positive test. Only 15 (71%) of
the 21 secondary cases with recruitment results were positive on
either test. Furthermore 4 Mantoux positive secondary cases were
ELISPOT negative and 4 ELISPOT positive secondary cases were
Mantoux negative. The results of this study have implications for the
design of trials of new interventions, particularly vaccines, in Africa,
and the revision of current guidelines for TB control.
The 33 (1.5%) co-prevalent cases and the 26 secondary cases
identified in this study population can be compared with the
number identified in other TB case contact studies, although few
have presented incidence rates of secondary disease - which can
only be calculated when the total person time of follow-up is
Figure 1. Study profile.
doi:10.1371/journal.pone.0001379.g001
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Uganda, following 1206 contacts of 423 TB cases for 2 years. As in
our study, over half of the TB cases in these African TB contacts
were found at an initial screen - they identified 51 (4.2%) co-
prevalent cases and 25 secondary cases. The median age of the
secondary cases was 31 years and 13 (52%) were HIV positive.
The higher rate of HIV positivity compared to our study explains
a large part of the higher prevalence of cases at screening and the
larger relative number of secondary cases at follow-up. Further-
more, a higher proportion (66% vs 38%) of the Ugandan contacts
were Mantoux positive at recruitment, suggesting a higher
background rate of M. tuberculosis infection. Egsmose et al [3], as
part of a study in rural Kenya, found that 17 (4.3%) of 392 TB
case contacts became ‘tubercle bacilli excretor’ TB cases within
one year, after exclusion of those diagnosed with TB before
enrolment. Puffer et al [4] followed 1358 household contacts of
298 ‘sputum positive’ American TB cases in the 1940s for 8754
person years and identified 30 cases of clinical TB: the overall
attack rate of clinical TB was 690/100,000 person years. Ferebee
et al [5] found 479 (1.9%) cases of TB in 25,512 American
household contacts of TB cases (not limited to sputum smear
positive cases) in the 1950s. Of the remaining contacts 12,594 were
assigned not to receive isoniazid: in this group, 107 (0.8%)
secondary cases were identified over one year of follow-up; 62 of
these had pulmonary disease.
It is possible that we have underestimated the true number of
secondary cases in this study. Some of those who died may have had
TB, although this appeared unlikely in most from the verbal
autopsies. We also excluded some of those who had undergone TB
treatment,becausetheydidnotmeetourcriteria fordiagnosis.Some
of these individuals may well have had TB disease. We have also
shown that some casespreferentiallyaccess the government clinicfor
diagnosis in The Gambia, even with free access to the MRC study
clinic. While we are confident that we have captured those that were
diagnosedatthegovernment clinic,wesuspectstronglythat stigmais
a significant impediment to the acknowledgement of both symptoms
and to seeking a TB diagnosis and treatment in The Gambia and
many other African settings. Furthermore, as identified by
Guwatudde et al[2], the limitations of current diagnostic tools make
an underestimation of the true number of secondary cases possible,
especially in relation to the difficult diagnosis of TB in children.
Under-diagnosis of secondary TB in children would lead to a
selection bias, if present, and has implications for the interpretation
of age as a predictor of progression to disease.
This study sheds new light on the appropriateness of major TB
guidelines, in particular the NICE guidelines – the results do not
support the two-step appraoch that is advocated,[16] at least in
settings such as The Gambia. Using such an approach, only seven of
the21progressorsinourstudy,thatwereinitiallytestedbybothtests,
would have been eligible for preventive treatment. This compares to
15 who were positive on one or other test. These results were
consistent with those obtained when considering only the initial
results of those six contacts with an isolate concordant by genotyping
with that of their respective index case. Few data from other studies
are available to shed more light on this issue. In a retrospective study
of practice in 120 child TB suspects in Newcastle, Taylor et al[24]
identified 5 TB cases: 4 had a positive Mantoux test at the beginning
of the investigations, 3 had a positive Quantiferon T cell assay test.
This, together with the results presented here, suggest caution in the
application of the NICE guidelines.
One might consider, as an alternative strategy, preventive treat-
ment for those who are positive on either test. A possible approach
would be to treat all those who are Mantoux positive, then perform a
T cell based test on those who are Mantoux negative, treating those
with a positive result. Thus, instead of testing all Mantoux positive
individuals with a T cell assay as is recommended, one would test all
Mantoux negative individuals. These issues can be considered in
terms of numbers needed to treat to prevent one TB case. From our
results, 60 Mantoux positive contacts need to be treated to prevent a
case, compared to 59 ELISPOT positive contacts and 90 contacts
Figure 2. Timing of presentation for diagnosis of incident TB cases after exposure to their respective index case.
doi:10.1371/journal.pone.0001379.g002
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plus those skin test negative contacts that are ELISPOT positve, 56
would need to be treated to prevent one TB case. These calculations
assume 100% efficacy of prophylactic treatment, which would be
expected to be less than 90% in reality [25].
It would be important to consider repeating each test in those
initially negative as we have previously shown that some who later
become cases, converted to a positive test 3 months after the initial
screen [15]. Furthermore, it is of note that even those TB case
contacts that were both Mantoux and ELISPOT negative had an
incidence rate of secondary disease of 400/100,000 person years.
This compares to the incidence rate of all cases of TB of 242/
100,000 per year for the whole Gambian population (http://www.
who.int/globalatlas/predefinedreports/tb/PDF_Files/gmb.pdf),
regardless of Mantoux and/or ELISPOT status prior to progression
to disease. One could therefore make a case, in making policy for
prophylactic treatment, for treating all those who have a known
contact with a sputum smear positive TB case in The Gambia and
similar settings. International guidelines presently suggest such a
strategy only in Mantoux negative individuals with a particular
susceptibility to develop TB disease[26]. Of relevance to The
Gambia and other African countries in particular, HIV positive
individuals cleary fall into this category.
The results of the molecular genotyping provide insights into the
TB case contact model as a platform for TB research in The
Gambia: six (67%) of the nine pairs of index cases and secondary
cases with isolates available were concordant. Therefore, the other
three secondary cases acquired their M. tuberculosis from someone
other than their respective index case, most probably from outside
theirhousehold.Themixofintra-andextra-householdtransmission
likely varies according to the degree of TB endemnicity in the
general population. In highly endemic suburbs of Capetown, South
Africa, for example, isolates match on molecular subtyping in less
than half (46%) of households with two TB patients, and the authors
estimated that only 19% of M. tuberculosis transmission occurs within
households [27]. Therefore, one should be cautious when interpret-
ing findings from TB case contact studies, taking into account the
level of community transmission outside households and molecular
genotyping on index case and secondary case isolates should be
performed when possible.
This results of this study have implications for research, clinical
and public health practice. The incidence rate that we have
documented here can form a guide for those choosing to use a TB
case contact study platform for research. While approximately 5 to
6% of Mantoux or ELISPOT positive TB case contacts develop TB
within 2 years in The Gambia, the majority are already cases at
initial screening and it is clear that multi-site studies, with a higher
overall case yield, may be needed to answer certain research
questions. Suchconsortia arealready being established. For example
a Gates Grand Challenge projectacross multipleAfrican sites utilises
a TB case contact study model[28]. Two key conclusions can be
drawn from the ELISPOT and Mantoux test results. Firstly, it seems
that certain individuals respond preferentially to one or the other
test, at leastinthe earlystages of M.tuberculosisinfection. Thismay be
Table 1. Baseline information of TB case contacts who progressed to disease (n=26) and those who did not (n=2322).
..................................................................................................................................................
Characteristic Progressors (n=26) Non-progessors (n=2322) HR (95% CI) p-value Adj HR (95% CI) Adj p-value
Age, years
0.5–10 7 (26.9) 861 (37.1) 1.0 1.0
11–25 10 (38.5) 891 (38.4) 1.4 (0.5–3.6) 1.1 (0.4–2.9)
.25 9 (34.6) 590 (25.4) 1.9 (0.7–5.0) 0.46 1.2 (0.4–3.4) 0.95
Mean (STD) 24.8 (17.6) 18.6 (15.5)
Median (range) 21.5 (2–70; IQR 10–27) 15.5 (0.5–100; IQR 7–25)
Sex
Female 15 (57.7) 1236 (53.2) 1.0
Male 11 (42.3) 1086 (46.8) 0.8 (0.4–1.7) 0.55
Ethnic group
Mandinka 5 (19.2) 749 (32.3) 1.0 1.0
Wolof 6 (23.1) 305 (13.1) 2.7 (0.9–8.0) 3.4 (1,1–11.0)
Fula 2 (7.7) 198 (8.5) 1.5 (0.3–4.3) 1.7 (0.3–9.3)
Jola 10 (38.5) 614 (26.4) 3.4 (1.0–11.3) 5.1 (1.4–18.5)
Other 3 (11.5) 456 (19.6) 1.0 (0.2–4.3) 0.16 1.4 (0.3–6.1) 0.085
Sleeping proximity to a TB case
Different house 6 (23.1) 727 (31.0) 1.0
Different room 14 (53.8) 1092 (46.6) 1.5 (0.6–4.0)
Same room 6 (23.1) 523 (22.3) 1.5 (0.5–4.5) 0.68
HIV status (n=2009)
Negative 22 (88) 1938 (97.7) 1.0 1.0
Positive 3 (12) 46 (2.3) 6.0 (1.8–20.0) 0.020 6.2 (1.7–22.5) 0.010
BCG scar status
Absent/uncertain 18 (69.2) 1349 (58.1) 1.0 1.0
Present 8 (30.8) 973 (41.9) 0.6 (0.3–1.4) 0.25 0.7 (0.3–1.8) 0.51
Data are n(%), unless otherwise stated.
doi:10.1371/journal.pone.0001379.t001
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PLoS ONE | www.plosone.org 5 January 2008 | Issue 1 | e1379due to varying incubation periods, as we have indicated previous-
ly[15], or there may be a more fundamental immunological basis.
Thus, both tests may be best used together at an initial screen –
perhapstotestfirstwithMantouxandallthosethatarenegativewith
ELISPOT-this takes advantage of the likelihood that ELISPOT is
probably not subject to the booster phenomenon[29]. Secondly,
where contact with an index case continues throughout treatment
and conversion of both the Mantoux and ELISPOT tests occur over
time[15], repeated testing should be considered. At a wider public
health policy level, these results do not support replacement of the
Mantoux test with a T cell based test for the diagnosis of TB
infection, at least in settings such as The Gambia.
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Table 2. Characteristics and type of TB in secondary cases, their recruitment Mantoux and ELISPOT results and details of the
molecular genotyping results of index case and secondary case isolates if available.
..................................................................................................................................................
Age
(yrs) Sex BCG scar Type of TB
*
Time to
illness
(months)
HIV
status Sleep prox
Mantoux
(mm)
Mantoux
(pos/neg)
ELISPOT ESAT-6
(spots/2610
5)
ELISPOT CFP-10
(spots/2610
5)
ELISPOT
(pos/neg)
Same
isolate
2 F No EPTB 4.7 Neg Diff house 0 Neg 3 0 Neg -
6 F Unsure EPTB 4.4 Neg Diff room 0 Neg 0 17 Pos -
6 M No EPTB 7.7 Neg Same room 30 Pos 111 12 Pos -
7 F Yes SPXRPTB 4.7 Neg Same room ND ND ND ND ND -
8 F No SPCPTB 6.3 Neg Diff room 17.5 Pos ND ND ND No
10 F No SNXRPTB 3.6 Neg Diff house 5 Neg 58 2 Pos -
10 M Yes SNCPTB 5.6 Neg Same room 0 Neg 0 0 Neg Yes
14 M No SPXRPTB 6.9 Neg Diff room 23.5 Pos 34 6 Pos -
16 F Yes SPCPTB 24.9 Neg Diff room 21.5 Pos 92 19 Pos Yes
18 F Unsure SPXRPTB 4.9 Neg Diff room 0 Neg 1 1 Neg -
19 F Yes SNCPTB 20.9 Neg Diff room 18 Pos 7 3 Neg Yes
21 M No SNCPTB 3.1 Neg Diff room 15.5 Pos ND ND ND -
21 M Yes SPXRPTB 15.6 Neg Same room 22.5 Pos 1 0 Neg -
22 F Yes SPXRPTB 11.2 Neg Diff room 14 Pos 8 0 Pos -
22 M Unsure SPCPTB 14.5 Neg Diff room 13 Pos 0 0 Neg Yes
23 M No SPCPTB 2.1 Neg Diff house 17 Pos 92 117 Pos No
25 F No SPXRPTB 14.7 ND Diff room 16 Pos ND ND ND -
26 M Unsure SPCPTB 18.7 Neg Same room 20 Pos 61 8 Pos Yes
27 F No SPXRPTB 7.3 Pos Diff room 0 Neg ND ND ND -
27 M Unsure SPCPTB 24.8 Neg Diff room 0 Neg 3 9 Pos Yes
40 M No SPXRPTB 4.3 Pos Same room 0 Neg 2 4 Neg -
45 M Yes SPXRPTB 14.6 Neg Diff room 0 Neg 0 0 Neg -
46 F No SPXRPTB 23.9 Pos Diff house 20 Pos 185 26 Pos -
53 F No SPXRPTB 4.8 Neg Diff room 15.5 Pos 2 0 Neg -
60 F Unsure SNCNXRPTB 20.4 Neg Diff house 0 Neg 14 17 Pos -
70 F Yes SNCPTB 19.7 Neg Diff house 0 Neg 1 3 Neg No
*Abbreviations used: EP, extrapulmonary; SPXRP, sputum positive/X-ray positive; SNXRP, sputum negative/X-ray positive; SNCP, sputum negative/culture positive; SPCP,
sputum positive/culture positive; SNCNXRP, sputum negative/culture negative/X-ray positive
doi:10.1371/journal.pone.0001379.t002
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
Table 3. Incidence rate of progression to disease, in TB case
contacts, according to initial Mantoux and/or ELISPOT results.
......................................................................
Mantoux/ELISPOT result
Progressors/
population
Incidence/100,000 person
years (95% confidence
interval)
All 26/2348 (1.1%) 603 (370–830)
Mantoux + 14
a/843 (1.7%) 902 (430–1370)
Mantoux 2 11
a/1387 (0.8%) 431 (180–680)
ELISPOT + 11
b/649 (1.7%) 924 (380–1460)
ELISPOT 2 10
b/1087 (0.9%) 502 (190–810)
Mantoux +/ELISPOT + 7
c/428 (1.6%) 886 (240–1540)
Mantoux + or ELISPOT + 15
c/835(1.8) 980 (570–1390)
Mantoux +/ELISPOT 2 4
c/230 (1.7%) 959 (20–1900)
Mantoux 2/ELISPOT + 4
c/177 (2.3%) 1242 (30–2450)
Mantoux 2/ELISPOT 2 6
c/813 (0.7%) 400 (80–720)
a25 cases and 2205 non-progressors had a Mantoux test;
b21 cases and 1715 non-progressors had an ELISPOT done;
c21 cases and 1627 non-progressors had both a Mantoux and ELISPOT test
done.
doi:10.1371/journal.pone.0001379.t003
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
Follow-Up of TB Contacts
PLoS ONE | www.plosone.org 6 January 2008 | Issue 1 | e1379REFERENCES
1. Jackson-Sillah D, Hill PC, Fox A, Brookes RH, Donkor SA, et al. (2007)
Screening for tuberculosis among 2381 household contacts of sputum-smear-
positive cases in The Gambia. Trans R Soc Trop Med Hyg 101: 594–601.
2. Guwatudde D, Nakakeeto M, Jones-Lopez EC, Maganda A, Chiunda A, et al.
(2003) Tuberculosis in household contacts of infectious cases in Kampala,
Uganda. Am J Epidemiol 158: 887–898.
3. Egsmose T, Ang’awa JO, Poti SJ (1965) The use of isoniazid among household
contacts of open cases of pulmonary tuberculosis. Bull World Health Organ 33:
419–433.
4 .P u f f e rR R ,Z e i d b e r gL D ,D i l l o nA ,G a s sR S ,H u t c h e s o nR H( 1 9 5 2 )
Tuberculosis attack and death rates of household associates; the influence of
age, sex, race, and relationship. Am Rev Tuberc 65: 111–127.
5. Ferebee SH, Mount FW (1962) Tuberculosis morbidity in a controlled trial of
the prophylactic use of isoniazid among household contacts. Am Rev Respir Dis
85: 490–510.
6. Lienhardt C, Fielding K, Sillah JS, Bah B, Gustafson P, et al. (2005)
Investigation of the risk factors for tuberculosis: a case-control study in three
countries in West Africa. Int J Epidemiol 34: 914–923.
7. Hill PC, Jackson-Sillah DJ, Donkor SA, Otu J, Adegbola RA, et al. (2006) Risk
factors for tuberculosis: a clinic-based case control study in The Gambia. BMC
Public Health 6: 156.
8. Ewer K, Deeks J, Alvarez L, Bryant G, Waller S, et al. (2003) Comparison of T-
cell-based assay with tuberculin skin test for diagnosis of Mycobacterium
tuberculosis infection in a school tuberculosis outbreak. Lancet 361: 1168–1173.
9. Mazurek GH, LoBue PA, Daley CL, Bernardo J, Lardizabal AA, et al. (2001)
Comparison of a whole-blood interferon gamma assay with tuberculin skin
testing for detecting latent Mycobacterium tuberculosis infection. JAMA 286:
1740–1747.
10. Pai M, Gokhale K, Joshi R, Dogra S, Kalantri S, et al. (2005) Mycobacterium
tuberculosis infection in health care workers in rural India: comparison of a
whole-blood interferon gamma assay with tuberculin skin testing. JAMA 293:
2746–2755.
11. Hill PC, Brookes RH, Fox A, Fielding K, Jeffries DJ, et al. (2004) Large-scale
evaluation of enzyme-linked immunospot assay and skin test for diagnosis of
Mycobacterium tuberculosis infection against a gradient of exposure in The
Gambia. Clin Infect Dis 38: 966–973.
12. Hill PC, Brookes RH, Adetifa IM, Fox A, Jackson-Sillah D, et al. (2006)
Comparison of enzyme-linked immunospot assay and tuberculin skin test in
healthy children exposed to Mycobacterium tuberculosis. Pediatrics 117:
1542–1548.
13. Ewer K, Millington KA, Deeks JJ, Alvarez L, Bryant G, et al. (2006) Dynamic
Antigen-specific T-Cell Responses after Point-Source Exposure to Mycobacte-
rium tuberculosis. Am J Respir Crit Care Med 174: 831–839.
14. Pai M, Joshi R, Dogra S, Mendiratta DK, Narang P, et al. (2006) Serial testing
ofhealthcareworkersfortuberculosisusinginterferon-gammaassay.AmJRespir
Crit Care Med 174: 349–355.
15. Hill PC, Brookes RH, Fox A, Jackson-Sillah D, Jeffries DJ, et al. (2007)
Longitudinal Assessment of an ELISPOT Test for Mycobacterium tuberculosis
Infection. PLoS Med 4: e192.
16. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures
for its prevention and control (2006). London: National Institute for Health and
Clinical Excellence, Clinical Guideline 33. 66 p.
17. Adegbola RA, Hill P, Baldeh I, Otu J, Sarr R, et al. (2003) Surveillance of drug-
resistant Mycobacterium tuberculosis in The Gambia. Int J Tuberc Lung Dis 7:
390–393.
18. van Embden JD, Cave MD, Crawford JT, Dale JW, Eisenach KD, et al. (1993)
Strain identification of Mycobacterium tuberculosis by DNA fingerprinting:
recommendations for a standardized methodology. J Clin Microbiol 31:
406–409.
19. Kamerbeek J, Schouls L, Kolk A, van Agterveld M, van Soolingen D, et al.
(1997) Simultaneous detection and strain differentiation of Mycobacterium
tuberculosis for diagnosis and epidemiology. J Clin Microbiol 35: 907–914.
20. Jeffries DJ, Hill PC, Fox A, Lugos M, Jackson-Sillah DJ, et al. (2006) Identifying
ELISPOT and skin test cut-offs for diagnosis of Mycobacterium tuberculosis
infection in The Gambia. Int J Tuberc Lung Dis 10: 192–198.
21. Ferrara G, Losi M, D’Amico R, Roversi P, Piro R, et al. (2006) Use in routine
clinical practice of two commercial blood tests for diagnosis of infection with
Mycobacterium tuberculosis: a prospective study. Lancet 367: 1328–1334.
22. Schim van der Loeff MF, Sarge-Njie R, Ceesay S, Awasana AA, Jaye P, et al.
(2003) Regional differences in HIV trends in The Gambia: results from sentinel
surveillance among pregnant women. AIDS 17: 1841–1846.
23. Jeffries DJ, Donkor S, Brookes RH, Fox A, Hill PC (2004) Design and
implementation of relational databases relevant to the diverse needs of a
tuberculosis case contact study in the Gambia. Int J Tuberc Lung Dis 8:
1095–1099.
24. Taylor RE, Cant AJ, Clark JE (2007) Potential impact of NICE tuberculosis
guidelines in paediatric TB screening. Arch Dis Child (In press).
25. Ferebee SH (1970) Controlled chemoprophylaxis trials in tuberculosis. A general
review. Bibl Tuberc 26: 28–106.
26. (2005) Guidelines for the investigation of contacts of persons with infectious
tuberculosis. Recommendations from the National Tuberculosis Controllers
Association and CDC. MMWR Recomm Rep 54: 1–47.
27. Verver S, Warren RM, Munch Z, Richardson M, van der Spuy GD, et al.
(2004) Proportion of tuberculosis transmission that takes place in households in a
high-incidence area. Lancet 363: 212–214.
28. Kaufmann SH, Parida SK (2007) Changing funding patterns in tuberculosis.
Nat Med 13: 299–303.
29. Hill PC, Jeffries DJ, Brookes RH, Fox A, Jackson-Sillah D, et al. (2007) Using
ELISPOT to expose false positive skin test conversion in tuberculosis contacts.
PLoS ONE 2: e183.
Follow-Up of TB Contacts
PLoS ONE | www.plosone.org 7 January 2008 | Issue 1 | e1379